Stockholm - Free Realtime Quote SEK
Fluicell AB (publ) (FLUI.ST)
As of 9:24 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,297.0000
3,338.0000
3,251.0000
2,602.0000
4,635.0000
--
Cost of Revenue
1,527.0000
1,600.0000
663.0000
715.0000
988.0000
--
Gross Profit
-230.0000
1,738.0000
2,588.0000
1,887.0000
3,647.0000
--
Operating Expense
26,900.0000
28,617.0000
24,314.0000
23,582.0000
20,673.0000
--
Operating Income
-27,130.0000
-26,879.0000
-21,726.0000
-21,695.0000
-17,026.0000
--
Net Non Operating Interest Income Expense
485.0000
849.0000
311.0000
2.0000
-564.0000
--
Pretax Income
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Net Income Common Stockholders
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Diluted NI Available to Com Stockholders
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Basic EPS
0.20
-0.23
-0.21
-0.38
-0.31
--
Diluted EPS
0.20
-0.23
-0.21
-0.38
-0.31
--
Basic Average Shares
455,118.9020
117,042.1550
105,320.5990
57,606.2710
57,606.2710
--
Diluted Average Shares
455,118.9020
117,042.1550
105,320.5990
57,606.2710
57,606.2710
--
Total Operating Income as Reported
-27,131.0000
-26,879.0000
-21,726.0000
-21,695.0000
-17,026.0000
--
Total Expenses
28,427.0000
30,217.0000
24,977.0000
24,297.0000
21,661.0000
--
Net Income from Continuing & Discontinued Operation
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Normalized Income
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Interest Income
506.0000
879.0000
358.0000
29.0000
--
--
Interest Expense
21.0000
30.0000
47.0000
27.0000
564.0000
--
Net Interest Income
485.0000
849.0000
311.0000
2.0000
-564.0000
--
EBIT
-27,149.0000
-26,524.0000
-21,559.0000
-21,666.0000
-17,026.0000
--
EBITDA
-26,661.0000
-25,914.0000
-20,839.0000
-21,078.0000
-16,421.0000
--
Reconciled Cost of Revenue
1,527.0000
1,600.0000
663.0000
715.0000
988.0000
--
Reconciled Depreciation
488.0000
610.0000
720.0000
588.0000
605.0000
--
Net Income from Continuing Operation Net Minority Interest
-27,170.0000
-26,554.0000
-21,606.0000
-21,693.0000
-17,590.0000
--
Normalized EBITDA
-26,661.0000
-25,914.0000
-20,839.0000
-21,078.0000
-16,421.0000
--
12/31/2019 - 4/18/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
COMBI.ST CombiGene AB (publ)
2.4600
0.00%
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1800
-2.17%
ACE.ST Ascelia Pharma AB (publ)
2.2400
+1.59%
ISOFOL.ST Isofol Medical AB (publ)
3.6250
-8.23%
9RP.F Lipigon Pharmaceuticals AB (publ)
0.0010
-16.67%
RESP.ST Respiratorius AB
0.0578
0.00%
ACTI.ST Active Biotech AB (publ)
0.2895
-1.70%
WNT.ST WntResearch AB
0.9000
0.00%
SPRINT.ST Sprint Bioscience AB (publ)
1.7800
0.00%
ELIC.ST Elicera Therapeutics AB (publ)
1.5550
+1.63%